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Abstract
Uncoupling protein-2 (UCP2) is known to suppress mitochondrial reactive oxygen species (ROS) production and is
employed by drug-resistant cancer cells to mitigate oxidative stress. Using the drug-sensitive HL-60 cells and the drug-
resistant MX2 subline as model systems, we show that genipin, a UCP2 inhibitor, sensitizes drug-resistant cells to cytotoxic
agents. Increased MX2 cell death was observed upon co-treatment with genipin and different doses of menadione,
doxorubicin, and epirubicin. DCFH-DA fluorimetry revealed that the increase in MX2 cell death was accompanied by
enhanced cellular ROS levels. The drug-induced increase in ROS was linked to genipin-mediated inhibition of mitochondrial
proton leak. State 4 and resting cellular respiratory rates were higher in the MX2 cells in comparison to the HL-60 cells, and
the increased respiration was readily suppressed by genipin in the MX2 cells. UCP2 accounted for a remarkable 37% of the
resting cellular oxygen consumption indicating that the MX2 cells are functionally reliant on this protein. Higher amounts of
UCP2 protein were detected in the MX2 versus the HL-60 mitochondria. The observed effects of genipin were absent in the
HL-60 cells pointing to the selectivity of this natural product for drug-resistant cells. The specificity of genipin for UCP2 was
confirmed using CHO cells stably expressing UCP2 in which genipin induced an ,22% decrease in state 4 respiration. These
effects were absent in empty vector CHO cells expressing no UCP2. Thus, the chemical inhibition of UCP2 with genipin
sensitizes multidrug-resistant cancer cells to cytotoxic agents.
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Introduction
Intrinsic or acquired drug resistance to chemotherapeutic agents
represents a great obstacle facing the successful eradication of
cancers [1]. The ability of cancer cells to evade drug toxicity is
attributed to the induction of elaborate detoxification mechanisms.
Indeed, the chronic exposure of cancer cells to chemotherapeutic
agents can elicit pro-survival responses characterized by the
enhanced ability to render chemotherapeutics innocuous [2,3].
Although cancer cells invoke numerous strategies to nullify toxins,
tight control over ROS levels represents a major adaptive response
[4]. Ensuring that ROS levels remain in the non-toxic range is a
continuous challenge for cancer cells Indeed, cancer cells are
continually exposed to high levels of ROS produced by
compromised aerobic metabolism, chemotherapeutics, nutrient
deprivation, and host immune responses [5,6,7]. If left unchecked
these singlet electron carriers can damage essential cellular
macromolecules leading to cell death [8,9]. Hence, a suite of
anti-oxidative defense strategies are invoked by cancer cells to
maintain ROS levels within tolerable limits.
The induction of UCP2 represents one of the many adaptive
mechanisms invoked by drug-resistant cells to maintain ROS
homeostasis [10,11]. UCP2 belongs to the mitochondrial anion
carrier superfamily and holds high homology to the original
mitochondrial uncoupling protein that is highly selectively
expressed in brown fat, UCP1 [12]. Various studies have shown
that UCP2 can prevent oxidative stress by increasing the flow of
protons into the matrix thus rendering electron flow through the
respiratory complexes more efficient [13,14,15]. This function of
UCP2 may be especially important in cancer cells since their
mitochondria are metabolically abnormal [16].
ROS are an inherent by-product of aerobic respiration since
mitochondrial respiratory complexes I and III can partake in the
singlet electron reduction of diatomic oxygen [17]. Roughly 0.2–
2% of the O2 metabolized by the mitochondria is converted to
ROS [18]. However, ROS generation can be greatly enhanced by
conditions that over-supply reducing equivalents to the respiratory
complexes thereby increasing mitochondrial membrane potential
(Dym). In fact, it has been reported in several studies that ROS
formation by the respiratory chain is strongly dependent upon
Dym [19,20]. Thus, even slight depolarization of the Dym can
enhance electron flow through the complexes and diminish
mitochondrial ROS production. UCP2 may fulfill this uncoupling
role in cancer cells; other reports describe the expression of other
uncoupling proteins, including UCP3 and UCP5 in adenocarci-
noma and colon cancer cells [21,22]. Indeed, various in vivo and in
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oxidative phosphorylation and limits oxidative injury to tissues
while loss of UCP2 function increases mitochondrial ROS
production [13,23,24,25,26]. Furthermore, the uncoupling activity
of UCP2 is thought to provide a negative feedback loop for the
acute control of ROS formation by mitochondria [27]. Thus,
UCP2 may play an integral role in the adaptive response of cancer
cells to chemotherapeutics.
Inhibiting drug-resistance mechanisms represents one method
for sensitizing cancer cells to chemotherapeutics [21,22]. UCP2
overexpression has been described in various types of cancer
including leukemia cells, human colon cancer cells, thyroid
tumours, and hepatomas [28,29,30,31]. Very recently, UCP2
knock-down has also been shown to enhance the toxic effects of
the chemotherapeutic cisplatin [32]. More intriguingly, UCP2
overexpression has been suggested to be part of the adaptive
mechanism required for the survival of cancer cells in adverse
environments [11]. For instance, overexpression of UCP2 in
HCT116 human colon cancer cells diminishes the pro-apoptotic
effects of the chemotherapeutics, etoposide and doxorubicin [33].
This was also observed with drug-resistant L1210/DDP leukemia
cells which use UCP2 to quench chemotherapy-induced ROS
through a proton leak mechanism [10]. Thus, UCP2 may
represent a unique target for the sensitization of drug-resistant
cells to chemotherapeutics. The aim of the current study was to
test the hypothesis that genipin, an extract from Gardenia jasminoides
which has been shown to inhibit UCP2 and improve insulin
secretion, can inhibit UCP2 in the drug resistant MX2 cancer cells
to increase oxidative stress and susceptibility to cytotoxic agents.
Genipin has been shown to be a highly selective inhibitor of
UCP2. Indeed, several studies have provided evidence that
genipin specifically impedes UCP2 mediated proton leak in
pancreatic b-cells, kidney mitochondria, and in brain tissue
[34,35]. Of note also is the fact that genipin is a traditional
Chinese remedy for the treatment of type 2 diabetes mellitus [35].
Results and Discussion
Genipin sensitizes drug-resistant leukemia cells to ROS
toxicity
The emergence of drug resistant cancer phenotypes is accompa-
nied by the acquisition of efficient control over ROS homeostasis.
UCP2 is an important modulator of ROS production in drug-
resistant cancer cells [10,11]. This mitochondrial inner membrane
protein is expressed at high levels in drug-resistant cells and has been
shown to play a key role in curtailing oxidative stress [10,36]. Thus,
we sought to determine if chemical inhibition of UCP2 could render
drug-resistant cells more sensitive to cytotoxic agents. The drug-
resistant MX2 cells displayed increased resistance to the superoxide-
producing menaquinone, menadione (Figure 1A). Menadione
produces ROS by rapidly cycling between the quinone and
semiquinone state and is used frequently to mimic oxidative stress
[37].Indeed,HL-60 viability decreased substantially upon treatment
with 10 mM menadione. Furthermore, exposure of HL-60 cells to
100 mM menadione resulted in a 90% decrease in cell viability.
However,the MX2 cells retained cellviability with concentrations of
menadione up to 100 mM( Figure 1A). Immunoblot analyses
revealed that the mitochondria from the MX2 cells contained higher
amounts of UCP2 protein (Figure 1B). In contrast to other studies,
we found that the anti-N19 antibody provided a very clear
chemiluminescent signal [38]. The electrophoretic mobility of
UCP2 was confirmed using spleen lysate. The anti-C20 antibody
did not provide a signal even with the spleen lysate (data not shown).
Immunoblot analyses revealed only slight increases in other anti-
oxidative defense enzymes in the MX2 cells (Figure 1B). Hence,
although the drug-resistant MX2 cells increase several anti-oxidative
defense enzymes to increase ROS handling, UCP2 displays the
greatest increase in expression when compared to the drug-sensitive
HL-60 counterpart. The specificity of genipin for UCP2 was
confirmed using CHO cells stably transfected with either UCP2 or
empty vector control. Immunoblotting confirmed that UCP2 is
expressed only in the CHO-UCP2 cells (Figure 1C). The single
band in each lane of the immunoblots also aligned at ,32 KDa
indicating the specificity of the antibody for UCP2 protein. In situ
bioenergetic determinations on CHO cells stably transfected with
UCP2 or empty vector were used to test the specificity of genipin.
Measurement of basal OCRprior to genipintreatmentrevealed that
the CHO-UCP2 cells displayed a significantly higher oxygen
consumption rate that was ,18% more elevated than the CHO-
EV cells (852.523645.838 OCR/mg of protein CHO-UCP3 vs
721.352615.050 OCR/mg of protein CHO-EV, p,0.05, n=3).
However, genipin treatment (20 and 50 mM) lead to an 12 and 22%
decrease in the OCR of the CHO-UCP2 cells in comparison to the
CHO-EV cells (Figure 1C). Hence, these data clearly illustrate the
specific inhibitory action of genipin on UCP2. It is worthy to note
that genipin treatment had no effect on the OCR of the CHO-EV
cells illustrating the specificity of genipin for UCP2.
It is clear from the above data that MX2 cells express high
amounts UCP2 and genipin specifically inhibits UCP2. Next we
evaluated if genipin could sensitize the MX2 cells to menadione
toxicity. As well as its use in treating type 2 diabetes, genipin has
been employed to treat glioma, hepatomas, and has anti-
inflammatory properties [35,39,40,41]. However, a dearth of
information exists on genipin toxicity. Our results show that
genipin concentrations higher than 50 mM resulted in the loss of
cell viability in both HL-60 and MX2 cultures (Figure 1D). This
is most likely due to its protein crosslinking abilities. Genipin
crosslinking results in the production of a blue pigment. However,
no blue pigment was observed at concentrations of genipin
,100 mM (data not shown). Concentrations below 50 mM had no
significant impact on the viability of either the MX2 or HL-60
cells. More importantly, exposure of MX2 cells to a combination
of 20 mM menadione and genipin (concentration as low as 10 mM)
resulted in a sharp decline in cell viability (Figure 1D). There was
an increase in MX2 viability upon exposure to ,100 mM genipin
in combination with menadione however there was still a
significant decrease in viability when compared to control. The
sensitizing effect of genipin to menadione was confirmed using the
PI assay. Exposure of MX2 cells for 24 h to 20 mM menadione in
the presence of 10 or 20 mM genipin resulted in a 2-fold and 8-fold
increase in cell death, respectively (Figure 1E). In contrast,
concentrations of menadione $50 mM were required to induce
MX2 death when genipin was absent (Figure S1). In addition, the
increase in cell death was several-fold higher when genipin was
included. Propidium iodide uptake can occur in both necrotic and
apoptotic cells. Thus, we measured several apoptosis markers. No
active caspase-3 was detected and cytochrome C was absent from
the cytosol consistent with the induction of necrosis (data not
shown). Although these two apoptosis biomarkers were not
detected, a more in-depth analysis of the mechanism of cell death
is required. We also assessed the impact of different amounts of
genipin on the non-cancerous C2C12 myoblast cell line. C2C12
myoblasts displayed an increase in cell death when treated with
$50 mM genipin (Figure S1). These observations indicate that
genipin does not induce a significant loss in cell viability at
concentrations below 50 mM and the effects of genipin on the
MX2 cells are due to its interactions with UCP2. Despite these
observations, more in vivo analyses on the toxicity of genipin and its
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required. Thus, genipin sensitizes drug-resistant cells expressing
UCP2 to ROS-producing agents.
Genipin sensitizes MX2 cells to anthracyclin toxicity
Menadione has been shown to have an anti-cancer effect and
has been employed with mitomycin C in phase II trials to treat
advanced lung cancer [42]. However, menadione is not currently
employed as a cancer chemotherapeutic. Thus, we determined if
genipin could sensitize the MX2 cells to commonly used
chemotherapeutics, specifically the quinone-based anthracyclins,
doxorubicin and epirubicin. MX2 cells are well known to be
resistant to this class of chemotherapeutics [43]. As shown in
Figure 2A, the MX2 cells were more resistant to increased
Figure 1. Genipin sensitizes drug-resistant MX2 cells to menadione toxicity. A) The viability of HL-60 (filled diamond) and MX2 (filled
square) following exposure to menadione. Cells were exposed for 24 h to different concentrations of menadione (0–100 mmol/L) followed by the
assessment of the number of live cells. Viability was expressed as a percent of the control value. Kruskall-Wallis with a post-hoc Mann-Whitney test,
n=3, p,0.05. * indicates statistical significance for HL-60 cells compared to control and # indicates statistical significance for MX2 compared to
control. B) Immunoblot analysis of anti-oxidant defense enzymes and UCP2. Mitochondria from MX2 (M) and HL-60 (H) cells were isolated and
analyzed for UCP2, MnSOD, and GPx4. Cytosol was used for G6PDH determinations. NADP-ICDH served as the loading control for the cytosol and
mitochondrial fractions. Spleen lysate (100 mg) was used as a UCP2 loading control. The molecular weight of UCP2 was confirmed using molecular
mass markers. C) In situ analysis of the specificity of genipin for UCP2. Following the determination of basal oxygen consumption rates, the impact of
genipin on OCR in CHO-UCP2 (white bars) cells was assessed. Cells were exposed to (0–50 mM) genipin for 15 min and then OCR was tested. Data was
expressed as a % of CHO-EV OCR. INSET: immunoblot analysis of UCP2 in CHO-UCP2 and CHO-EV cells. SDH served as the loading control. Kruskall-
Wallis with a post-hoc Mann-Whitney test, n=3, p,0.05. * indicates statistical significance when compared to the control. D) Assessment of genipin
toxicity and the response of drug-sensitive HL-60 and drug-resistant MX2 cells to simultaneous treatment with menadione and genipin. Cells were
exposed to genipin (0–500 mmol/L) in the presence or absence of 20 mM menadione for 24 h. Following the exposure, cell viability was determined.
¤ and & represent exposure to either genipin or genipin + menadione. Viability was expressed as a percent of the control. Kruskall-Wallis with a
post-hoc Mann-Whitney test, n=3, p,0.05. * corresponds to statistical significance when cells exposed to both menadione and genipin were
compared to control. # corresponds to statistical significance when genipin-exposed cells were compared to the control cells. E) Treatment with
genipin and menadione increases MX2 cell death. MX2 cells were exposed to 20 mmol/L menadione and genipin (0–500 mmol/L) for 24 h. The
amount of cell death was determined using the PI assay. 1-way ANOVA with a post-hoc Tukey’s test, n=5, p,0.05. * represents significance when
compared to 0 mM.
doi:10.1371/journal.pone.0013289.g001
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sensitive counterpart. However, sharp increments in cell death
were observed in the genipin-treated MX2 cells exposed to
increasing amounts of epirubicin (Figure 2A). Curiously, genipin
and epirubicin (0.05–0.1 mM) co-treatment increased cell death in
the HL-60 cells but this response was nullified at higher doses
epirubicin (0.5 mM, MX2 cells displayed a 4-fold increase whereas
the HL-60 cells displayed a 2-fold increase). MX2 cells were also
resistant to doxorubicin treatment (Figure 2B). Intriguingly, the
HL-60 cells only displayed a trend toward increased cell death,
however statistical significance was not reached (0.05–0.5 mM
doxorubicin, only a 20–40% increase; p.0.05). The major
observation in Figure 2B is the significant increase in MX2 cell
death upon treatment with genipin and doxorubicin (0.05–
0.5 mM; ,50–110%; p,0.05). The sensitizing effect of genipin
was not observed in the HL-60 cells treated with doxorubicin
which is consistent with the inhibitory action of genipin on UCP2.
Use of epirubicin and doxorubicin concentrations above 1 mMi n
combination with genipin resulted in drastic increases in the cell
death of HL-60 and MX2 cells (data not shown). Hence, genipin
disarms chemotherapeutic resistance in drug-resistant cells over-
expressing UCP2.
Genipin treatment perturbs aerobic respiration in
drug-resistant cells
Despite the glycolytic phenotype of cancer cells, the enzymatic
machinery required for aerobic respiration frequently remains
intact [44]. Maintenance of functional mitochondria is crucial for
the cancer cell, e.g., the Krebs cycle enzymes provide anabolic
precursors for rapidly dividing cells [6]. Our group has shown
previously that mitochondria in drug-resistant leukemia cells are
uncoupled and that this is associated with decreased cellular ROS
levels [10]. Thus, we hypothesized that the sensitizing effect of
genipin was due to its ability to prevent UCP2-mediated
uncoupling of the Dym. As shown in Figure 3A, the basal rate
of oxygen consumption was higher in the MX2 when compared to
HL-60 cells (,54% greater, p,0.05). This indicates that the
mitochondria in MX2 cells are more metabolically active than
HL-60 mitochondria. Treatment of HL-60 and MX2 cells with
oligomycin decreased respiration by ,60% and ,38% respec-
tively (Figure 3A). This indicates that ,62% of the resting
cellular O2 consumption in the MX2 cells is due to uncoupled
respiration (e.g. non-ATP producing activities). Sharp deviations in
mitochondrial metabolism often accompany the acquisition of
aggressive cancer phenotypes [6]. Indeed, targeted disruption of
mitochondrial metabolism has been described as a potential
cancer therapy [2]. Pre-treatment with genipin significantly
diminished basal respiration in the MX2 cells (Figure 3A). These
effects were not seen in the HL-60 cells. Genipin induced a ,37%
decrease in the respiratory rate revealing that UCP2 is
quantitatively important in maintaining an uncoupled mitochon-
drial phenotype even under standard incubation conditions. In
comparison, the CHO-UCP2 cells experienced a ,22% decline in
OCR following treatment with 50 mM genipin (Figure 1C). The
Figure2. Genipin sensitizes MX2 cells toepirubicinanddoxorubicin. HL-60 andMX2 cells were grown to 70% confluencyandthen exposed to
either epirubicin (0–0.5 mM) or doxorubicin (0–0.5 mM) in the absence or presence of 20 mM genipin. Amount of cell death was determined by PI assay.
Results were expressed as a percent of the control. A) ¤ epirubicin only, & epirubicin + genipin. 1-way ANOVA with a post-hoc Tukey’s test, n=5,
*p ,0.05. * corresponds to statistical significance when epirubicin and genipin treated cells were compared to control. # corresponds to statistical
significance when epirubicin-treated cells were compared to control cells. B)¤ doxorubicin only, & doxorubicin + genipin. 1-way ANOVA with a post-
hoc Tukey’s test, n=5, p,0.05. * corresponds to statistical significance when epirubicin and genipin treated cells were compared to control cells.
doi:10.1371/journal.pone.0013289.g002
Genipin and Drug-Resistance
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13289discrepancy between the CHO and MX2 cells is most likely due to
the differences in dose and the time of exposure between the two
separate cells lines. This observation indicates overall that UCP2 is
a major contributor to MX2 cellular bioenergetics. Moreover,
following the addition of genipin to oligomycin-treated MX2 cells,
the respiration rate was identical to that of the HL-60 cells
(Figure 3A). This indicates that UCP2 was entirely responsible for
the increased respiration of MX2 cells. Several studies have shown
that genipin specifically inhibits UCP2-mediated uncoupling
[34,45]. For instance, Zhang et al illustrated that proton leak is
not affected by genipin in UCP2
2/2 cells and in tissue that does
not express UCP2 [35]. We observed similar trends in the CHO
cells exposed to genipin (Figure 1C). Hence, genipin completely
inhibits the increased cellular respiration in the MX2 cells, while it
has no effect on the HL-60 parent cells.
UCP2 is known to be a negative regulator of mitochondrial
ROS production, a property attributed to its mild uncoupling
activity. In two elegant studies, Echtay et al provided convincing
evidence that UCP2-mediated proton conductance is maximally
activated by oxidative stress in the mitochondria [27,46]. This type
of ‘‘inducible’’ proton leak has been described as an important
safeguard in preventing increases in mitochondrial ROS emission.
Thus, we tested if ROS treatment could increase proton leak in the
MX2 cells. Menadione treatment did not alter oxygen consump-
tion in the MX2 cells (Figure 3B). These data indicate that ROS
did not cause further increases in proton leak dependent
respiration. However, in the HL-60 cells, menadione treatment
significantly diminished oxygen consumption, perhaps due to the
diminished ability of these cells to control cellular ROS levels
(Figure 3B). Mitochondrial metabolism (e.g., citric acid cycle
enzymes and electron transport chain proteins) is a major target
for ROS toxicity. Thus, the decrease in oxygen consumption
observed in the HL-60 cells exposed to menadione indicates these
cells have a lower capacity to maintain tolerable levels of cellular
ROS in the presence of cytotoxic agents. The above data establish
that UCP2 prevents ROS-induced impairments in mitochondrial
metabolism. In other words, the low abundance of UCP2 in the
HL-60 cells may mean that they are unable to detoxify the ROS.
In the MX2 cells, our results support the conclusion that UCP2 is
already maximally activated. Indeed, in two separate experiments
(Figure 3A and 3B) genipin diminished oxygen consumption by
,37% in cells under standard incubation conditions. Further-
more, nonphosphorylating respiration accounted for ,62% of the
O2 consumption in the MX2 cells and genipin inhibited over half
of this respiration, resulting in the normalization of non-
phosphorylating respiration (i.e., to HL-60 values). Hence, UCP2
accounts for a large fraction of the nonphosphorylating respiration
in MX2 cells. Thus, the unique metabolic profile of the drug-
Figure 3. Genipin decreases cellular oxygen consumption in drug-resistant MX2 but not drug-sensitive HL-60 cells during
oligomycin-induced state 4 respiration. A) Oxygen consumption measurements in cells exposed to 20 mM genipin 24 h exposure. Oxygen
consumption measurements were performed following a 30 min incubation in reaction medium in the absence (white bars) or presence (grey bars)
of oligomycin. 1-way ANOVA with a post-hoc Tukey’s test, n=6, **p,0.01. Treated MX2 or HL-60 cells were only compared with their corresponding
control mean values. B) Oxygen consumption measurements in cells exposed to genipin (20 mM) and/or menadione (20 mM) for 24 h. 1-way ANOVA
with a post-hoc Tukey’s test, n=4, *p,0.05,
doi:10.1371/journal.pone.0013289.g003
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mitochondrial uncoupling to avoid the cytotoxic effects of drug-
and mitochondrial-borne ROS.
Treatment with genipin enhances drug-induced ROS
production
The above data indicate that the inhibition of UCP2 by genipin
results in the induction of drug-induced cell death in multidrug
resistant MX2 cells. Since UCP2 inhibition sensitizes cells to
ROS-producing agents, we then tested if genipin treatment
enhanced drug-induced ROS formation. HL-60 cells treated with
menadione alone produced far more ROS than their drug-
resistant counterpart (Figure 4A). This observation is consistent
with the enhanced ROS handling capacity of drug-resistant cells.
However, the co-treatment of MX2 cells with genipin and
menadione increased ROS levels. Indeed, exposure of genipin-
treated MX2 cells to different amounts of menadione resulted in
increased ROS levels (Figure 4B). At 50 mM menadione, there
was a sharp increase in ROS levels in the genipin-exposed MX2
cells. Only moderate increases in ROS production were observed
in the HL-60 cells treated with menadione and genipin
(Figure 4B). Treatment with genipin alone in MX2 cells did
not increase ROS levels (Figure 4B). Thus, genipin renders the
MX2 cells more sensitive to treatment with ROS producing agents
by interfering with proton leak.
Similar observations were made with doxorubicin. Doxorubicin
is classically referred to as a topoisomerase II inhibitor [47].
However, other mechanisms of toxicity, such as ROS production,
have been suggested [48]. Treatment with doxorubicin alone
resulted in a dose-dependent increase in ROS levels in HL-60 cells
(Figure 5A). In contrast, no increases in ROS were observed in
the MX2 cells even at 1 mM. However, when genipin was included
with the doxorubicin, increases in ROS levels were observed in the
MX2 cells (Figure 5B). Indeed, exposure of genipin-loaded cells
to concentrations of doxorubicin as low as 0.1 mM resulted in a
sharp increase in ROS levels. Although doxorubicin is widely used
as an anticancer agent, its mechanism of action is not fully
understood. In this study, we show that doxorubicin can increase
ROS levels in the MX2 cells upon co-treatment with genipin. It is
quite possible that doxorubicin toxicity targets the mitochondria.
The anthracyclins are quinone molecules, like menadione, which
are capable of catalyzing the singlet electron reduction of diatomic
oxygen to superoxide. Superoxide, at high enough concentrations,
interferes with the proper functioning of the mitochondria.
Figure 4. Genipin treatment increases menadione-mediated ROS levels in drug-resistant cells. ROS levels were assessed in intact HL-60
and MX2 cells using DCFH-DA. A) ROS levels in cells exposed to solely menadione (0–50 mM) for 24 h. 1-way ANOVA with a post-hoc Tukey’s test,
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menadione in MX2 cells required genipin treatment. It is entirely
possible that the drug-resistant cells cope with the inhibitory effects
of doxorubicin and quinones by maintaining mitochondria in an
uncoupled state limiting ROS formation.
Our findings indicate that the natural product genipin can render
drug-resistant cancer cells more sensitive to ROS-producing agents.
The clinical application of genipin as a potential drug-sensitizing
agent requires further investigation. Indeed, the drug-sensitizing
effects of genipin were examined herein with commonly studied
lines of cancer cells. Hence, to provide more clarity on the potential
role of genipin in cancer treatment, comprehensive in vivo analyses
are now required (e.g., animal studies). However, this study provides
some important preliminary insights into the potential use of
genipin in cancer treatment. In this study, the sensitizing effect of
genipin was attributed its interaction with UCP2, a protein
abundantly expressed intheMX2cell mitochondria. Thespecificity
of genipin for UCP2 was confirmed with CHO cells stably
expressing UCP2. HL-60 cells were unresponsive to genipin
treatment which is most likely attributed to the low amounts of
UCP2 expressed in these cells. The specific inhibitory action of
genipin was confirmed using CHO cells either expressing or not
expressing UCP2. Thus, our findings are consistent with a specific
effect of genipin on UCP2. UCP2 is expressed in a number of
normal somatic cells (splenocytes, pancreatic b cells, thymus cells,
and various other immune-type cells) [26]. The amount expressed
in drug-resistant cancer cells greatly exceeds the protein levels in
non-cancerous cells and drug-sensitive cancer cells. Low UCP2
proteinlevelsaremaintainedbytighttranslationalcontroland rapid
degradation [49]. Curiously, glutamine has been implicated in the
induction of UCP2 mRNA translation [50] and drug-resistant
cancer cells have enhanced glutamine uptake and metabolism, a
process mediated by Myc [51]. Thus, it is possible that glutamine
dependence plays a part in enhancing UCP2 protein expression in
drug-resistant cells. It would be interesting to determine if UCP2
canbe induced by Myc. In this study,themechanismfor the UCP2-
mediated reduction in ROS stems from its uncoupling activity.
Indeed, in MX2 cells UCP2 was responsible for over a third of
resting cellular respiration, and approximately 60% of state 4
respiration. Other ROS detoxification mechanisms were enhanced
in the MX2 cells however UCP2 displayed the greatest increase in
abundance indicating that uncoupling plays a key role in controlling
ROS levels. Further research is required to specifically address the
possibility that UCP2 could be targeted by cell permeable
compounds, such as genipin, to augment the effectiveness of
cytotoxic strategies in cancer treatment.
Figure 5. Genipin treatment enhances the production of ROS by doxorubicin. ROS levels were assessed in intact HL-60 and MX2 cells using
DCFH-DA. A) ROS levels in HL-60 cells and MX2 cells exposed to doxorubicin (0–1 mM) for 24 h. 1-way ANOVA with a post-hoc Tukey’s test, n=5,
*p,0.05, **p,0.01. B) ROS levels in HL-60 cells and MX2 cells exposed to 20 mM genipin and doxorubicin (0–1 mM) for 24 h. 1-way ANOVA with a
post-hoc Tukey’s test, n=5, *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013289.g005
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Cell lines and treatment
The drug-sensitive and drug-resistant human acute promyelo-
cytic leukemia (APL) suspension cell lines HL-60 and HL-60/MX2
(MX2) were purchased from the American Type Culture Collection
on May 6 2009 (ATCC, Manassas, Virginia). Selection for
sensitivity and resistance to chemotherapeutics and authentication
were performed by ATCC prior to shipping. Upon receiving the
cells were propagated and prepared for cryogenic storage according
to the instructions providedbyATCC.Cellswereroutinelycultured
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 20% (v/v) fetal bovine serum (FBS), 4 mM L-glutamine,
25 mM dextrose, 1 mM pyruvate, and 1% (v/v) antibiotics/
antimycotics. Cells were cultured up to 15 passages and then
discarded. Cells were provided with fresh media every 48 h. For
experimentation, cells were grown to 70% confluency and then
provided fresh media containing genipin (0–500 mM), menadione
(0–100 mM), doxorubicin (0–10 mM), or epirubicin (0–10 mM).
Cells were exposed to the different conditions for 24 h. Cells were
then isolated and treated accordingly for each assay.
CHO cells stably transfected with either pcDNA3.1 vector
containing UCP2 (CHO-UCP2) or empty vector (CHO-EV) were
a gift from Dr. Fre ´de ´ric Bouillaud [50]. CHO cells were routinely
maintained in Matrigel-coated T75 cm
2 flasks in DMEM
containing 20% FBS and 2% antibiotics/antimycotics. Media
was changed every two days and cells were passaged every four
days. For the immunodetection of UCP2, cells were grown to
confluency in Matrigel-coated 6-cm
2 dishes and then lysed on ice
with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1%
NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM NaF, 1 mM
Na3VO4, 1 mM PMSF, and protease inhibitors). Cells were
scraped from the dish and then prepared for immunoblot. Protein
content was determined using the BCA assay.
Cell Viability and Survival Assays
Cell survival following genipin, menadione, doxorubicin, or
epirubicin exposure was ascertained using cell viability and
Propidium Iodiode (PI) assays. For viability assays, the Trypan
Blue exclusion method was employed [52]. Briefly, an aliquot of
the cell suspension was diluted in Trypan Blue solution
(Invitrogen, Burlington, Ontario) and cell viability was determined
using the Countess Cell Counter according to the manufacturer’s
instructions (Invitrogen, Burlington, Ontario). For PI assays, cells
were washed three times with washing buffer (PBS +10 mM
dextrose) and then incubated for 10 min in PI (10 mg/mL in PBS).
PI solution was removed and cells were washed twice. Cells were
then placed in a 96-welled plate and read at an excitation
wavelength of 530 nm and an emission wavelength of 615 nm
(Biotek FLX-800, Fisher). PI results were normalized to protein
content using the Bradford assay. PI (1 mg/mL) was purchased
from Sigma (St Louis, Missouri).
C2C12 myoblast culture
C2C12 myoblasts were routinely cultured in Matrigel coated 6-
cm
2 dishes in DMEM consisting of 25 mmol/L dextrose,
4 mmol/L L-glutamine, 20% (v/v) fetal bovine serum, and 1%
(v/v) antibiotics/antimycotics. To assess the toxicity of genipin
against a non-cancer cell line, C2C12 cells were seeded at
10,000 cells/mL in a final volume of 200 mL in Matrigel coated
96-welled dishes. Cells were grown to confluency and then treated
with genipin (0–500 mM) for 24 h. The cell monolayer was then
washed with PBS and treated with PI assay medium as described
above. Following several washings, the degree of PI fluorescence
associated with the cell monolayer was determined. The assay was
normalized to protein level using the Bradford assay (BioRad,
Mississauga, Ontario, Canada).
Impact of genipin on CHO cell bioenergetics
The Seahorse XF24 Extracellular Flux Analyzer (Seahorse
Bioscience, North Billerica, MA) was employed to determine the
impact of genipin on the mitochondrial bioenergetic characteris-
tics of CHO cells. CHO-UCP2 and CHO-EV cells were seeded at
50,000 cells/mL and grown to confluency in Matrigel-coated 24-
welled Seahorse plates. Analyses were conducted on 20 wells per
plate on three separate plates for an n=3. Mean values were then
calculated from the OCR per well in each plate following
correction to total amount of cellular protein per well. For
experiments, cells were then incubated for 30 min at 37uCi n
HCO3-free DMEM containing 10 mM glucose, 4 mM L-
glutamine, and 1 mM pyruvate (pH 7.0). Fluorimetric sensors
enabled the sensitive in situ measurement of O2 consumption rate
(OCR). Measurement of OCR was performed over 2 min in three
measurement intervals to assess basal metabolic rate (one
measurement interval includes 2 min mixing, 2 min incubation,
and 2 min measurement steps). Following the determination of
basal OCR, cells were exposed to genipin (0–50 mM) for 15 min
and then OCR was assessed. Data were expressed as percentages
of the CHO-EV respiration rates (OCR/mg of protein).
Measurement of cellular ROS levels
Intracellular ROS levels were assayed using 29,7 9-dichlorodihy-
drofluorescin diacetate (DCFH-DA; Invitrogen). Following expo-
sure to genipin (20 mM), menadione (0–50 mM), or doxorubicin (0–
1 mM) cells were counted to determine live cell concentration. Cells
were then harvested by centrifugation at 250 g for 5 min and
washed once with washing buffer. The cell pellet was then
resuspended in DMEM containing 20 mmol/L DCFH-DA. Cell
suspensions were then incubated for 30 min at 37uC under constant
agitation. Following two washes with washing buffer the cells were
resuspended in 1 mL of washing buffer. Fluorescence was recorded
using a 96-welled plate reader operating at an excitation/emission
wavelength of 485 nm/530 nm (Biotek FLX-800, Fisher). Mean
fluorescence values of DCFH-DA-loaded cells were corrected by
subtracting the autofluorescence background.
Measurement of oxygen consumption in HL-60 and MX2
cells
Measurements were performed as described in [10]. Cells
grown in the presence or absence of genipin (20 mM) or
menadione (20 mM) were harvested, washed once with washing
buffer and placed on ice prior to experimentation. Batches of
10610
6 cells were resuspended in 1 mL of reaction medium
(106 mmol/L NaCl, 0.41 mmol/L MgCl2, 25 mmol/L
Na2HPO4, 5 mM KCl, 10 mM dextrose, pH 7.0) and incubated
for 30 min at 37uC. Oligomycin (10 mg/mL) was included in the
reaction medium to determine the contribution of proton leak to
oxygen consumption. The cell suspension was then placed in the
temperature-regulated Clark-type electrode chamber (Oxytherm;
Hansatech Instruments Ltd, Norfolk England). Oxygen consump-
tion was measured for 5-15 min (until oxygen consumption
ceased) at 37uC. The rate of oxygen consumption for each run
was determined using Oxytherm Plus software.
Mitochondrial isolation
Mitochondria were isolated using the protocol described in [53]
with some minor modifications. Briefly, 100610
6 cells were
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then resuspended in a slightly hypotonic mitochondrial isolation
buffer (250 mmol/L sucrose, 10 mmol/L Hepes, 1 mmol/L
EDTA, protease inhibitor cocktail (Roche, Mississauga, Ontario,
Canada), pH 7.4) and sonicated four times on ice for 10 seconds in
1 second bursts. After each sonication the cell suspension was
placed on ice for 5 min. The hypotonic medium provided an
enriched mitochondrial preparation as opposed the KCl-based
isotonic mitochondrial isolation media commonly employed. Cell
suspensions were then subjected to differential centrifugation to
isolate the mitochondria. To isolate mitochondria, the cell
suspensions were centrifuged at 2506g and 8506g for 10 min at
4uC to remove whole cells and nuclei. The supernatant was then
centrifuged at 12,0006g for 30 min at 4uC to yield the
mitochondrial pellet and a cytosolic fraction. Protein content
was determined using the Bradford assay (Bio-Rad, Mississauga,
Ontario, Canada).
Immunoblot analysis. Samples were diluted to 1 mg/mL in
Laemmli buffer and 30 mg of protein was electrophoresed on a
12% isocratic SDS-gel. Concentrated spleen lysate, which is
known to express UCP2, served as a control (100 mg of protein was
loaded and electrophoresed). Transfers to nitrocellulose
membranes were performed at room temperature at a voltage of
100V. The transfer buffer consisted of 1% (v/v) SDS to ensure
complete transfer of proteins. Transfer efficiency was tested by
Ponceau S staining of membranes and Coomassie R-250 staining
the gels. The membranes were blocked and probed for 1–24 h at
4uC with primary antibodies directed against UCP2 (anti-N19
and anti-C20, 1/2000 dilution, Santa Cruz), Mn-dependent
superoxide dismutase (MnSOD, 1/2000 dilution, Santa Cruz),
glucose-6-phosphate dehydrogenase (G6PDH, 1/3000 dilution,
Santa Cruz), and glutathione peroxidase (GPx, 1/1000 dilution,
Abcam). Various primary antibody dilutions were used to
optimize detection (1/200-1/5000). NADP-dependent isocitrate
dehydrogenase (ICDH, 1/2000, Abcam) was used as a loading
control for the cytosol and mitochondrial fractions (the ICDH
antibody reacts with both the cytosol and mitochondrial isoforms
of ICDH). Succinate dehydrogenase (SDH, 1/2000, Santa Cruz)
served as loading control for the CHO cells. Membranes were
then incubated for 1 h at room temperature with the requisite
horseradish peroxidase-conjugated secondary antibody (anti-
rabbit, anti-mouse, or anti-goat, 1/2000, Santa Cruz). Blots
were visualized using enhanced chemiluminescent substrate (ECL
kit, Thermo Scientific).
Statistical Analysis. One-way ANOVA with a post hoc
Tukey’s test and Kruskall-Wallis with a post-hoc Mann-Whitney
non-parametric test (Statview software, SAS Institute Inc., USA)
were used to assess statistical differences. All p values were
generated from the post-hoc tests. Results are expressed as mean
value +/2 standard deviation.
Supporting Information
Figure S1 A) Determination of cell death in MX2 cells exposed
to menadione (0–100 mmol/L). Following a 24 h exposure to
menadione, amount of cell death was determined using the PI
assay. Data were expressed as a percent of the control. 1-way
ANOVA with a post-hoc Tukeys test, n=5, **p,0.01. All treated
means were compared to the control mean. B) Toxicity of genipin
towards noncancer cells. Confluent C2C12 cells were exposed to
genipin (0–500 mM) for 24 h and the degree of cell death was
determined by PI assay. 1-way ANOVA with a post-hoc Tukeys
test, n=4, *p,0.05. All treated means were compared to the
control mean.
Found at: doi:10.1371/journal.pone.0013289.s001 (0.02 MB
PDF)
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